RxDoctor Payments Data

Danille Prime, MD

Pulmonary Disease · Wilmington, NCNPI 1366702847

Payments from drug & device makers

$26,967in general payments, 2019–2025

Across 104 payments — averaging $259.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$22K
  • Mylan Specialty L.p.$3K
  • AstraZeneca$688
  • Jazz Pharmaceuticals Inc.$266
  • GSK$248
  • Boehringer Ingelheim$245
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$18,14167%
  • Speaking & faculty fees$2,93711%
  • Travel & lodging$2,78310%
  • Food & beverage$2,81510%
  • Education$2921%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,967 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$17,800
Medicare patients
69
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate15$198,186
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$47,595
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$24,413
Stiolto RespimatTiotropium Br/Olodaterol Hcl37$21,201
Spiriva RespimatTiotropium Bromide15$12,083
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,806
Combivent RespimatIpratropium/Albuterol Sulfate12$6,704
Advair HfaFluticasone Propion/Salmeterol15$6,526
XareltoRivaroxaban12$6,436
Roflumilast58$3,624
Albuterol Sulfate HfaAlbuterol Sulfate63$1,712
Ventolin HfaAlbuterol Sulfate15$825
Pantoprazole Sodium16$318
Fluticasone Propionate14$209
Montelukast Sodium23$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$245$238,17579 claims
GSKTrelegy Ellipta, Anoro Ellipta$248$56,40083 claims
AstraZenecaBreztri Aerosphere$688$24,41335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →